2'-氧代-1',2'-二氢螺[哌啶-4,3'-吡咯并[2,3-B]吡啶]-1-羧酸叔丁酯 | 885031-86-7

• 物质功能分类: 无机化工 - 单质
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 2'-氧代-1',2'-二氢螺[哌啶-4,3'-吡咯并[2,3-B]吡啶]-1-羧酸叔丁酯
• 英文名称: tert-butyl 2'-oxo-1',2'-dihydro-1H-spiro[piperidine-4,3'-pyrrolo[2,3-b]pyridine]-1-carboxylate
• 英文别名: tert-butyl 2'-oxo-1',2'-dihydro-1H-spiro[piperidine-4,3'-pyrrolo[2.3-b]pyridine]-1-carboxylate；tert-butyl 2'-oxo-1',2'-dihydro-1H-spiro[piperidine-4,3'-pyrrolo[2,3-]pyridine]-1-carboxylate；tert-Butyl 2'-oxo-1',2'-dihydrospiro[piperidine-4,3'-pyrrolo[2,3-b]pyridine]-1-carboxylate；tert-butyl 2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,4'-piperidine]-1'-carboxylate
• CAS: 885031-86-7
• 化学式: C₁₆H₂₁N₃O₃
• 分子量: 303.361
• InChiKey: ZEJLWODBJNBBKT-UHFFFAOYSA-N

物化性质

• 沸点：
  496.4±45.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2'-氧代-1',2'-二氢螺[哌啶-4,3'-吡咯并[2,3-B]吡啶]-1-羧酸叔丁酯 在 盐酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 3.0h， 以2.25 g的产率得到螺哌啶-4,3’-3H吡咯并[2,3-b]吡啶-2’(1’H)-酮
  参考文献：
  名称：

  A spirocyclic oxindole analogue: Synthesis and antitumor activities

  摘要：

  A new synthesis of spirocyclic oxindole analogue spiro[piperidine-4,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 1 is described. The key steps involve dialkylation of arylacetonitrile and cyclization of the azaoxindole ring by an intramolecular Buchwald Hartwig amidation of carboxylic amide and aryl chloride. A small library was obtained by reductive amination of 1 with various aldehydes and was screened against human lung cancer cell A549, human liver cancer cell BEL7402, and human colon cancer cell HCT-8. The results show that most of the library compounds 2 have some inhibitory activities. 2-(Trifluoromethoxy) benzylic substituted spirocyclic azaoxindole 2e was identified as a nanomolar inhibitor against human lung cancer cell A-549 (IC50 = 50 nmol/L). (C) 2011 Da Wei Teng. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  DOI：

  10.1016/j.cclet.2011.01.042
• 作为产物：
  描述：

  2-氯-3-吡啶甲醇 在 1,1'-双(二苯基膦)二茂铁 、 tris-(dibenzylideneacetone)dipalladium(0) 、 磺酰氯 、 双氧水 、 sodium hydride 、 sodium hydroxide 、 sodium t-butanolate 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 21.33h， 生成 2'-氧代-1',2'-二氢螺[哌啶-4,3'-吡咯并[2,3-B]吡啶]-1-羧酸叔丁酯
  参考文献：
  名称：

  A spirocyclic oxindole analogue: Synthesis and antitumor activities

  摘要：

  A new synthesis of spirocyclic oxindole analogue spiro[piperidine-4,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 1 is described. The key steps involve dialkylation of arylacetonitrile and cyclization of the azaoxindole ring by an intramolecular Buchwald Hartwig amidation of carboxylic amide and aryl chloride. A small library was obtained by reductive amination of 1 with various aldehydes and was screened against human lung cancer cell A549, human liver cancer cell BEL7402, and human colon cancer cell HCT-8. The results show that most of the library compounds 2 have some inhibitory activities. 2-(Trifluoromethoxy) benzylic substituted spirocyclic azaoxindole 2e was identified as a nanomolar inhibitor against human lung cancer cell A-549 (IC50 = 50 nmol/L). (C) 2011 Da Wei Teng. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  DOI：

  10.1016/j.cclet.2011.01.042

文献信息

• [EN] SPIROHETEROCYCLIC DERIVATIVES AS CRHR2 ANTAGONIST<br/>[FR] DÉRIVÉS SPIROHÉTÉROCYCLIQUES UTILISÉS COMME ANTAGONISTES DE CRHR2
  申请人：RAQUALIA PHARMA INC

  公开号：WO2021145401A1

  公开（公告）日：2021-07-22

  The present invention relates to spiroheterocyclic derivatives which have antagonistic activities against CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR2 is involved.

  本发明涉及对CRHR2具有拮抗活性的螺环杂环衍生物，用于治疗或预防涉及CRHR2的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及CRHR2的疾病中使用这些化合物和组合物。
• Cgrp Receptor Antagonists
  申请人：Paone Daniel V.

  公开号：US20080261972A1

  公开（公告）日：2008-10-23

  Compounds of Formula (I), (where variables R 1 , A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  式(I)的化合物（其中变量R1、A、B、W、X、Y和Z如本文所定义），可用作CGRP受体的拮抗剂，并可用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗CGRP参与的这些疾病的方法。
• Heterocyclic benzodiazepine cgrp receptor antagonists
  申请人：Williams Theresa M.

  公开号：US20090105228A1

  公开（公告）日：2009-04-23

  Compounds of formula I: (where variables R 2 , R 7 , D, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  公式I的化合物：（其中变量R2，R7，D，W，X，Y和Z如本文所述），它们是CGRP受体的拮抗剂，并且可用于治疗或预防与CGRP有关的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗CGRP参与的这些疾病。
• SPIROAZAINDOLES
  申请人：Pierce (nee Fletcher) Joan M.

  公开号：US20110152304A1

  公开（公告）日：2011-06-23

  The present invention relates to spiroazaindole compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

  本发明涉及螺环氮吲哚化合物，可用作HIF脯氨酸羟化酶抑制剂，用于治疗贫血和类似疾病。
• CGRP RECEPTOR ANTAGONISTS
  申请人：Burgey Christopher S.

  公开号：US20100113419A1

  公开（公告）日：2010-05-06

  The present invention is directed to compounds of Formula I: Formula I: Formula II: (where variables R 1 , R 2 , R 3 , R 4 , A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及I式化合物：I式：II式：（其中变量R1、R2、R3、R4、A、B、J、Q、T、V、W、X和Y的定义如本文所述），用作CGRP受体拮抗剂，有助于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗CGRP参与的疾病方面的使用。